Controlled trial on the usefulness of pioglitazone treatment in patients with type 2 diabetes mellitus and COVID-19.

Phase 1

Active, not recruiting

• Conditions: COVID-19 in patients with diabetes mellitus type 2; Therapeutic area: Diseases [C] - Virus Diseases [C02]

• Registration Number: EUCTR2020-001929-31-ES
• Lead Sponsor: Fundación Investigación Biomédica Hospital Ramón y Cajal

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-22
• Last Update Posted: 27 July 2020

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

- Adult patients >18 years old
- Confirmed diagnosis of COVID-19 or high clinical suspicion according to current criteria.
- Previous diagnosis of DM2.
- Patients who provide their informed consent to participate in the study
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 46

Exclusion Criteria

- Patients under 18 years
- Known hypersensitivity to the active substance or any of the excipients of the drug.
- Known history of heart failure or situation at the time of initiation of the cardiac failure study.
- Liver failure.
- Dialysis
- Situation of diabetic ketoacidosis at the time of the start of the study.
- Diabetes mellitus other than type 2.
- Active bladder cancer or a history of bladder cancer
- Non-philated macroscopic hematuria
- Patients included in another experimental study with another drug.
- Entry into the Intensive Care Unit.
- Patients with mechanical ventilation requirement at the time of inclusion.
- Pregnancy
- Breastfeeding

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified